Respiratory ‘Call for Targets’ Issued to World’s Researchers
MRC Technology, an independent life science research charity, recently announced a ‘call for targets’ to find new therapeutic concepts for treatment
of respiratory disease.
The worldwide call to academic researchers offers the opportunity to
collaborate with MRC Technology’s Centre for Therapeutic Discovery (CTD) on
target validation and proof of concept prior to initiating a full scale drug
Interested researchers are asked to visit www.callfortargets.org/respiratory.
Through this call MRC Technology aims to identify and accelerate
projects focused on validation of potential small molecule or antibody targets,
in pathways important in the development or progression of respiratory
conditions. Respiratory conditions such as allergy, acute respiratory distress
syndrome (ARDS), asthma, chronic obstructive pulmonary disease (COPD),
pulmonary fibrosis, and cystic fibrosis currently affect an estimated 12
million people living in the UK.
The call draws on MRC Technology’s expertise in translating novel,
promising biology into lead stage therapeutics. Successful projects will
benefit from CTD’s wealth of experience in assay development, high throughput
screening (HTS), medicinal chemistry, antibody engineering and affinity maturation.
CTD will also provide academic researchers with access to an in-house small
molecule library as well as its core antibody humanization skills.
“MRC Technology’s model is based on sharing both the risks and the
rewards of drug discovery with its partners,” says Justin Bryans, Director of Drug
Discovery at MRC Technology. “Finding treatments for respiratory disease is a
clear area of unmet need, with COPD being the fifth biggest killer disease in
the U.K. This latest call for respiratory targets is strongly aligned to our
charitable aim of advancing scientific discoveries that can improve human
MRC Technology set up its CTD laboratories to support its technology
transfer and IP management efforts, to bridge the gap between innovative, early
stage academic research and the development of intellectual property suitable
for licensing to industry, for further development and commercialization.
De-risking novel targets by providing proof of concept and pharma-quality data
packages fulfills a clear need in the drug discovery process.